Quarterly ResultMay 7, 2026, 04:20 PM
Verastem Q1 Net Product Revenue $18.7M; Pipeline Updates
AI Summary
Verastem reported Q1 2026 net product revenue of $18.7 million, contributing to approximately $50 million in AVMAPKI FAKZYNJA CO-PACK net product revenue since its May 2025 launch. The company provided updates on its clinical pipeline, including the RAMP 301 confirmatory trial for LGSOC with topline data expected by mid-2027, and the advancement of VS-7375 for KRAS G12D-mutated cancers with Phase 2 trials expected to begin mid-2026. Verastem maintains a strong balance sheet with $181.7 million in cash, cash equivalents, and short-term investments as of March 31, 2026, and expects its AVMAPKI FAKZYNJA CO-PACK franchise to be self-sustaining in 2H 2026.
Key Highlights
- Q1 2026 Net Product Revenue reached $18.7M.
- Total AVMAPKI FAKZYNJA CO-PACK Net Product Revenue since launch (May 2025) is ~$50M.
- Cash, cash equivalents & short-term investments stood at $181.7M as of March 31, 2026.
- RAMP 301 Phase 3 trial for recurrent LGSOC expects topline primary endpoint data by mid-2027.
- VS-7375 Phase 2 registration-directed trials for KRAS G12D-mutated cancers expect First Patient In (FPI) by mid-2026.
- RAMP 205 (1L mPDAC) showed an 83% confirmed Objective Response Rate (ORR) in DL1 (n=12).
- AVMAPKI FAKZYNJA CO-PACK franchise is projected to be self-sustaining in 2H 2026.
Price Impact
More from VSTM